Physician profile
Mandeep Ayer
NPI 1205817111
$1,180.59
in general payments reported to CMS, 2019-2025
14 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $15.92 · 2021: $132 · 2022: $71.91 · 2023: $156 · 2024: $327 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $765 · Education: $18.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.54 |
| Education | $18.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $303.88 | 2021-2025 | |
| Novo Nordisk INC | $155.31 | 2019-2025 | Ozempic |
| Medtronic USA, INC. | $115.08 | 2019 | |
| Glaxosmithkline, LLC. | $106.52 | 2024-2025 | Trelegy Ellipta |
| Amgen INC. | $105.88 | 2024-2025 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals Lp | $97.76 | 2023-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $59.60 | 2019-2025 | Kisunla, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $57.76 | 2024 | |
| Exact Sciences Corporation | $47.09 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $40.53 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $34.66 | 2023-2025 | Dificid, Gardasil 9, Capvaxive |
| Xeris Pharmaceuticals, INC. | $19.59 | 2025 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $18.99 | 2023 | Evkeeza |
| Janssen Pharmaceuticals, INC | $17.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandeep Ayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.